Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.99M Buy
165,789
+135
+0.1% +$3.53K 3.28% 12
2026
Q1
$4.65M Sell
165,654
-368
-0.2% -$9.8K 4.19% 11
2025
Q4
$4.13M Buy
166,022
+1,129
+0.7% +$28.5K 3.72% 14
2025
Q3
$4.2M Buy
164,893
+281
+0.2% +$6.94K 3.78% 11
2025
Q2
$3.99M Buy
164,612
+1,924
+1% +$44.9K 3.66% 11
2025
Q1
$4.12M Buy
162,688
+16,888
+12% +$442K 4.13% 11
2024
Q4
$3.87M Buy
+145,800
New +$3.95M 3.86% 11

Other funds holding PFE

Drystone's PFE Position: Q2 2026 in Review

Drystone increased its Pfizer (PFE) stake by 0.08% in Q2 2026, buying an estimated $3.53K and bringing the position to 165,789 shares worth $3.99M. The position accounts for 3.28% of the portfolio, ranked #12.

Drystone first reported a position in PFE in Q4 2024 and has held it in 7 quarters since. The position peaked at $4.65M in Q1 2026. 900 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Drystone held 165,789 shares of Pfizer worth $3.99M as of Q2 2026.
  • Drystone bought 135 Pfizer shares in Q2 2026, an estimated $3.53K.
  • Pfizer made up 3.28% of Drystone's portfolio in Q2 2026, its #12 holding.
  • Drystone first reported a position in Pfizer in Q4 2024 and has held it in 7 quarters since.
  • Drystone's Pfizer position peaked at $4.65M in Q1 2026.
  • 900 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Drystone's 13F filing for Q2 2026, filed 24 Jul 2026.